A randomized, double-blind, placebo-controlled, parallel-design, 5-group, multinational study to evaluate the efficacy, dose response, and safety of tadalafil once-a-day dosing for 12 weeks in men with signs and symptoms of benign prostatic hyperplasia
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Tadalafil (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company; Lilly ICOS
- 19 Apr 2016 Results of a pooled analysis from four trials (n= 1462) published in the Journal of Urology
- 24 Aug 2015 Results of post-hoc analysis of pooled data from four trials published in the International Journal of Clinical Practice.
- 25 Aug 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.